Both the TYRX™ Neuro Absorbable Antibacterial Envelope and the TYRX™ Cardiac Absorbable Antibacterial Envelope for cardiac implantable electronic devices (CIEDs) are designed to help reduce infection, and they share many of the same features.
In cardiac cases, bacterial infection is one of the most common causes of complications, and the standard antibiotic prophylaxis have significant deficiencies when used as a single agent to prevent infection.1-2
The TYRX Absorbable Antibacterial Envelope helps reduce infection in high-risk patients and is more effective when combined with the standard treatment.3
Contributing factors for this increase:
Typically, the same anti-infective measures are used for all patients regardless of their risk of infection.17-18 Pre-operative IV antibiotic prophylaxis is routinely given one hour before first incision. Ninety percent of patients receive cephalosporin and/or vancomycin.
Perioperatively, the pocket is typically irrigated with antibiotic agents.
Approximately 45% of the time, oral antibiotics are prescribed after the procedure. IV antibiotics may be administered for 24 hours after the initial implant.
Greenspon A et al. J Am Coll Cardiol. 2011;58(10):1001-1006.
The Sanford Guide to Antimicrobial Therapy. Web Edition. 2015: Antimicrobial Therapy Inc.; Hyde Park, VT
Mittal S et al. Heart Rhythm. 2014; 11(4):595-601.
Sohail MR et al. PACE. 2015;38(2):231-239.
Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services Inpatient Prospective Payment System (IPPS) Final Rule FY13.
Bloom HL et al. Pacing Clin Electrophysiol. 2011; 34(2):133-142.
Kolek MJ et al. J Cardio Electrophysiol. 2015;26(10):1111-1116.
Shariff N et al. J Cardio Electrophysiol. 2015;26(10):783-789.
Henrikson CA et al. JACC EP 2017; 3 (10):1158-1167.
Wisplinghoff H et al. CID. 2004;39(3):309-317.
NNIS System Report. Am J Infect Control. 2004;32(8):470-485.
Klug D et al. Circulation. 2007;116(12):1349-1355.
Lekkerkerker JC et al. Heart. 2009;95(9):715-720.
de Oliveira JC et al. Circ Arrhyth Electrophysiol. 2009;2(1):29-34.
D a Costa A et al. Circulation. 1998;97(18):1791-1795.
Chua J et al. Ann Intern Med. 2000;133(8):604-608.
MEDACorp. Survey of 42 EPs and 30 cardiac lab supervisors, 2007. Sponsored by TYRX, Inc.
Easton Assoc. Survey of 24 EPs, 6 EP lab Mgrs. And RNs, 2008. Sponsored by TYRX, Inc.
Lansdown A et al. Issues in Toxicology. 2010; 5.3:123.
Percival SL et al. Wound Repair Regeneration. 2011; 19(6); 769-770. Online publication.
Argentum Medical. Silverlon® Product Brochure.
Townsend Letter for Doctors & Patients. April 2006; Issue 273: 66-72.
Zinner SH et al. J Infect Dis. 1981;144(4):365-371.
Darouiche RO et al. Int J Antimicrob Agents. 1995;6(1):31-36.
Segreti J et al. Diagn Microbiol Infect Dis. 1989;12(3):253-255.